Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

attention-deficit/hyperactivity disorder

PharmaDeviceNews attention-deficit/hyperactivity disorder

Representative image: Otsuka’s centanafadine Phase 3b results highlight the investigational ADHD treatment’s potential in adults with comorbid anxiety ahead of the FDA decision.

Pharma & Biotech

Could centanafadine reshape nonstimulant ADHD treatment after Otsuka’s Phase 3b success?

by Pallavi Madhiraju
June 27, 2026
0 Comments

Discover how Otsuka’s centanafadine Phase 3b ADHD data could shape FDA review and the nonstimulant treatment market. Read more.

Read More

Latest news and features

Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus
Teva wins FDA approval for DEGEVMA biosimilar across all Xgeva indications
One Carvykti infusion, five years without maintenance: Johnson & Johnson’s tiny trial delivers a striking myeloma signal
MediciNova stock up 85% in September as pivotal ALS trial reaches final patient visit
Merck KGaA’s $11.3bn Bio-Techne deal clears shareholder vote as life-science tools consolidation advances
FDA sets January decision for Pharming Group’s lower-dose Joenja pediatric expansion
Five-year CARVYKTI data deepen evidence for durable remission in earlier-line multiple myeloma
Eli Lilly just cut basal insulin dosing from 365 injections to 52. Can Onswik catch Novo Nordisk’s Awiqli?
Prime Medicine stock jumps after FDA clears PM647 gene-editing trial for alpha-1 antitrypsin deficiency
Merck’s $3bn EyeBio bet clears first pivotal test as remigromig matches Lucentis
Relay handed Lyrfigtu to Elevar for $5m upfront. FDA approval now tests the value of that unusual biotech deal
aTyr Pharma refocuses efzofitimod Phase 3 strategy on lung function after failed steroid endpoint

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

CleanMax secures Rs 2,500cr green bond financing at 8.25%–8.76% fixed coupons
FTAI Infrastructure’s Jefferson unit to buy $255m crude logistics assets from USD Group
NXP and Vanguard open $7.8bn Singapore chip factory with volume production set for 2027
du combines six 5G carriers across 420MHz in commercial Nokia deployment
Powerful US nor’easter leaves one dead as Northeast faces flooding, outages and travel chaos

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.